Monotherapy

Treg cells
#Kainova Therapeutics #Monotherapy #Tregs

Kainova Therapeutics doses first patient with cancer monotherapy 

Kainova Therapeutics has dosed the first patient with its Treg-depleting monotherapy.  The biopharmaceutical company dosed the patient in a Phase I/II clinical trial of DT-7012, a proprietary Treg depleting antiCCR8 monoclonal antibody, in patients with advanced solid tumours.  The study is evaluating DT7012 as monotherapy… Read More

#News

#AACR #Cancer research #Clinical trials #Monotherapy #Recursion #Solid tumours

Encouraging response for monotherapy dose-escalation study

Recursion has reported initial monotherapy dose-escalation data from the Phase I/II study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumours. These results were presented after market close at an AACR Special Conference in Cancer Research. “Cell cycle dysregulation and transcriptional ‘addiction’ are both hallmarks of many aggressive… Read More

#Cancer Research #News

#Biotechnology #Cancer #Fibrotic disease #Monotherapy #Small molecul #Therapeutics

Topline data from Phase II monotherapy module

Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, has shared topline monotherapy data from the biliary tract cancer (BTC) module of the RXC004 PORCUPINE2 Phase II clinical trial programme. RXC004 is an… Read More

#News